A business in context

OTLC research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-10-07 · 0001493152-26-046751 · Items 8.01,9.01

  2. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001493152-26-037857

  3. 8-K · Current report

    Report date 2026-08-03 · 0001493152-26-035999 · Items 1.01,2.03,3.02,9.01

  4. 4 · Ownership change

    Report date 2026-07-10 · 0001493152-26-034397

  5. 4 · Ownership change

    Report date 2026-07-10 · 0001493152-26-034069

  6. 8-K · Current report

    Report date 2026-07-13 · 0001493152-26-033172 · Items 8.01,9.01

  7. 8-K · Current report

    Report date 2026-07-10 · 0001493152-26-033171 · Items 3.02,5.02,9.01

  8. 4 · Ownership change

    Report date 2026-07-10 · 0001493152-26-033169

  9. 4 · Ownership change

    Report date 2026-07-10 · 0001493152-26-033168

  10. 4 · Ownership change

    Report date 2026-07-10 · 0001493152-26-033167

  11. 4 · Ownership change

    Report date 2026-07-10 · 0001493152-26-033166

  12. 4 · Ownership change

    Report date 2026-07-01 · 0001493152-26-031846

  13. 8-K · Current report

    Report date 2026-06-23 · 0001493152-26-031124 · Items 1.01,2.03,3.02,9.01

  14. 4 · Ownership change

    Report date 2026-06-22 · 0001493152-26-029997

  15. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001493152-26-023181

  16. 8-K · Current report

    Report date 2026-05-01 · 0001493152-26-021306 · Items 1.01,2.01,3.02,9.01

  17. 8-K · Current report

    Report date 2026-04-16 · 0001493152-26-016981 · Items 8.01,9.01

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001493152-26-016838

  19. 8-K · Current report

    Report date 2026-03-31 · 0001493152-26-014831 · Items 1.01,8.01,9.01

  20. 8-K · Current report

    Report date 2026-03-24 · 0001493152-26-013503 · Items 8.01,9.01

  21. 8-K · Current report

    Report date 2026-03-23 · 0001493152-26-013391 · Items 8.01,9.01

  22. 8-K · Current report

    Report date 2026-01-23 · 0001493152-26-004237 · Items 1.01,2.03,3.02,9.01

  23. 8-K · Current report

    Report date 2026-01-22 · 0001493152-26-003606 · Items 1.01,5.02,9.01

  24. 8-K · Current report

    Report date 2026-01-02 · 0001493152-26-000821 · Items 1.01,2.03,3.02,9.01

  25. 8-K · Current report

    Report date 2025-12-31 · 0001493152-26-000619 · Items 1.01,2.03,9.01

  26. 8-K · Current report

    Report date 2025-12-31 · 0001493152-26-000613 · Items 1.01,3.02,9.01

  27. 8-K · Current report

    Report date 2025-12-23 · 0001493152-25-029634 · Items 1.01,3.02,9.01

  28. 8-K · Current report

    Report date 2025-12-22 · 0001493152-25-028921 · Items 8.01,9.01

  29. 8-K · Current report

    Report date 2025-12-04 · 0001493152-25-026883 · Items 1.01,3.02,9.01

  30. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001493152-25-023834

  31. 8-K · Current report

    Report date 2025-10-21 · 0001493152-25-018877 · Items 8.01,9.01

  32. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001641172-25-023568

  33. 8-K · Current report

    Report date 2025-08-06 · 0001641172-25-023189 · Items 1.01,2.03,3.02,9.01

  34. 8-K · Current report

    Report date 2025-07-31 · 0001641172-25-022361 · Items 1.01,2.03,3.02,9.01

  35. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001641172-25-010984

  36. 10-K · Annual report

    Report date 2024-12-31 · 0001641172-25-004846

  37. 8-K · Current report

    Report date 2025-03-23 · 0001641172-25-000537 · Items 8.01,9.01

  38. 8-K · Current report

    Report date 2024-12-31 · 0001493152-25-000028 · Items 8.01,9.01

  39. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001493152-24-046867

  40. 10-Q · Quarterly report

    Report date 2024-06-30 · 0001493152-24-031995

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 1 transaction rows1PSale: 0 transaction rows0SGrant / award: 6 transaction rows6AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

7 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-07-10
2026-07-23
Fein Seymour HowardA · Grant / award
Acquired
Restricted stock Units
Derivative security
250.00.0
2026-07-10
2026-07-21
KING STEVEN WA · Grant / award
Acquired
Restricted stock Units
Derivative security
250.00.0
2026-07-10
2026-07-14
MAIDA ANTHONY E IIIA · Grant / award
Acquired
Restricted stock Units
Derivative security
1500.00.0
2026-07-10
2026-07-14
Saund SaranA · Grant / award
Acquired
Restricted stock Units
Derivative security
1500.00.0
2026-07-10
2026-07-14
Shah Amit B.A · Grant / award
Acquired
Restricted stock Units
Derivative security
1500.00.0
2026-07-10
2026-07-14
Trieu VuongA · Grant / award
Acquired
Restricted stock Units
Derivative security
2000.00.0
2026-07-01
2026-07-02
Trieu VuongP · Purchase
Acquired
Common Stock240000.00.04

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0000908259Oncotelic Therapeutics, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • MATEON THERAPEUTICS INC · former SEC name · 2016-06-17 to 2021-03-26
  • OXIGENE INC · former SEC name · 1996-10-24 to 2016-06-03

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2023-12-31$70.0K$77.4K
2020-12-31$1.74M$2.27M

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗